TGTX Latest Press Releases

-- November 2, 2026 --

TG Therapeutics to Host Conference Call on Third Quarter 2026 Financial Results and Business Update Business Wire 7:30 AM

-- October 23, 2026 --

TG Therapeutics Announces Phase 1 Data Evaluating Azer-cel in Progressive Multiple Sclerosis in a Late-Breaking Oral Presentation at MSToronto2026 Business Wire 10:55 AM

-- October 21, 2026 --

TG Therapeutics Highlights New Clinical Data Across Multiple Sclerosis Portfolio at MSToronto2026 Business Wire 8:52 AM

-- October 12, 2026 --

TG Therapeutics Announces Publication of Five-Year Comparative Analysis of BRIUMVI Versus Ocrelizumab and Ofatumumab in Relapsing Multiple Sclerosis Business Wire 7:30 AM

-- October 8, 2026 --

TG Therapeutics Announces Schedule of Data Presentations at MSToronto2026 Business Wire 7:30 AM

-- September 28, 2026 --

Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law Firm PRNewswire 9:09 AM

-- September 10, 2026 --

Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market Globe Newswire 8:30 AM

TG Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference Globe Newswire 7:30 AM

-- September 3, 2026 --

TG Therapeutics to Participate in the Cantor Global Healthcare Conference Globe Newswire 7:30 AM

-- August 6, 2026 --

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update Business Wire 7:01 AM

-- August 3, 2026 --

TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance Globe Newswire 7:00 AM

-- July 29, 2026 --

TG Therapeutics to Host Conference Call on Second Quarter 2026 Financial Results and Business Update Globe Newswire 7:30 AM

-- July 21, 2026 --

Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law Firm PRNewswire 5:20 PM

-- July 16, 2026 --

Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law Firm Globe Newswire 9:25 PM

-- July 6, 2026 --

TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia Globe Newswire 7:30 AM

-- June 24, 2026 --

The Quest to Repair What Multiple Sclerosis Takes Away Globe Newswire 8:30 AM

-- June 9, 2026 --

TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial Globe Newswire 7:30 AM

Market Data Delayed 15 Minutes